FWBI Live signals | Maximize Profits with Getagraph.com

BUY 107719 min ago

@ $5.43

Issued: 9 Feb 2024 @ 15:55

Return: -43.46%

Previous signal: Feb 7 - 14:00

Previous signal: Sell

Return: 5.44 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:52):

Stats
Today's Volume	6 139.00
Average Volume	114 446
Market Cap	6.22M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-2.18 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600
ATR14	$0.0750 (2.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Sapirstein James	Sell	174	Common Stock
2024-04-01	Romano Sarah	Sell	75	Common Stock
2024-03-15	Sapirstein James	Sell	1 887	Common Stock
2024-03-15	Romano Sarah	Sell	1 120	Common Stock
2024-03-13	Syage Jack	Buy	15 400	Common Stock, par value $0.0001 per share

INSIDER POWER
93.65
Last 95 transactions
Buy: 5 900 618 \| Sell: 1 318 677

Volume Correlation

Long: -0.01 (neutral)

Short: 0.88 (strong)

Signal:(46.723) Same movement expected

First Wave BioPharma, Correlation

10 Most Positive Correlations
PDSB	0.826
ALLK	0.815
NAKD	0.811
WTBA	0.81
FREE	0.809
LBPS	0.804
LYRA	0.804
TRIT	0.803
CMMB	0.801

10 Most Negative Correlations
BBIO	-0.836
NVDA	-0.834
LSCC	-0.834
ACVA	-0.828
PDFS	-0.827
BRKS	-0.823
OSW	-0.822
FTNT	-0.821
ADI	-0.821
RRGB	-0.82

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

First Wave BioPharma, Correlation - Currency/Commodity

-0.30
( neutral )

-0.01
( neutral )

0.00
( neutral )

0.18
( neutral )

0.08
( neutral )

0.22
( neutral )

First Wave BioPharma, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-29 274.00 (0.00 %)
EPS:	$-46.96

Q4	2023
Revenue:	$0
Gross Profit:	$-7 319.00 (0.00 %)
EPS:	$-2.63

Q3	2023
Revenue:	$0
Gross Profit:	$-23 413.00 (0.00 %)
EPS:	$-9.08

Q2	2023
Revenue:	$0
Gross Profit:	$-23 125.00 (0.00 %)
EPS:	$-36.89

Financial Reports:

No articles found.

First Wave BioPharma,

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.